Viking Therapeutics (VKTX) closed at $25.84 on November 19, 2026, down 1.3% from the previous close, on volume of 2,477,124 shares (30-day average 4,289,336).
Data as of November 19, 2026.
19-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 16, 2026 | Calendar Call Spread | 24-Dec : 31-Dec-26 30 C | 7,208 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
3 Best Growth Stocks to Buy Now with 100%+ Upside, According to Analysts
TipRanks (Wed, 18-Nov 10:13 AM ET)
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Seeking Alpha News (Tue, 17-Nov 12:22 PM ET)
Viking Therapeutics: Buy Rating and $118 Price Target Reaffirmed on VK-2735’s Competitive Potential
TipRanks (Tue, 17-Nov 10:55 AM ET)
Viking Advances Oral Weight-Loss Trial as Investors Watch for Phase 3 Data
TipRanks (Mon, 16-Nov 11:31 AM ET)
Viking Advances Oral Obesity Drug Study as VK2735 Enters Phase 3
TipRanks (Mon, 16-Nov 11:31 AM ET)
TipRanks (Mon, 16-Nov 6:45 AM ET)
Viking Therapeutics: Strong VK2735 Obesity Data Support Maintained $95 Price Target
TipRanks (Sun, 15-Nov 7:45 PM ET)
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek 2026
PRNewswire (Sun, 15-Nov 12:05 PM ET)
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek 2026
PRNewswire (Mon, 9-Nov 7:05 AM ET)
Viking Therapeutics Lines Up Five Investor Conferences as VK2735 Advances in Phase 3 Obesity Studies
Market Chameleon (Wed, 4-Nov 3:00 AM ET)
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Viking Therapeutics trades on the NASDAQ stock market under the symbol VKTX.
As of November 19, 2026, VKTX stock price declined to $25.84 with 2,477,124 million shares trading.
VKTX has a beta of 1.25, meaning it tends to be more sensitive to market movements. VKTX has a correlation of 0.07 to the broad based SPY ETF.
VKTX has a market cap of $3.30 billion. This is considered a Mid Cap stock.
In the last 3 years, VKTX traded as high as $99.41 and as low as $11.21.
The top ETF exchange traded funds that VKTX belongs to (by Net Assets): XBI, VTI, VB, VBK, VXF.
VKTX has underperformed the market in the last year with a price return of -31.6% while the SPY ETF gained +9.6%. VKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.6% and -7.6%, respectively, while the SPY returned -6.5% and -6.6%, respectively.
VKTX support price is $25.08 and resistance is $27.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VKTX shares will trade within this expected range on the day.